Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

2015

L30A Mutation of Phospholemman Mimics Effects of Cardiac
Glycosides on Isolated Cardiomyocytes
Ryan David Himes
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Physiology Commons

Recommended Citation
Himes, Ryan David, "L30A Mutation of Phospholemman Mimics Effects of Cardiac Glycosides on Isolated
Cardiomyocytes" (2015). Dissertations. 1639.
https://ecommons.luc.edu/luc_diss/1639

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2015 Ryan David Himes

LOYOLA UNIVERSITY CHICAGO

L30A MUTATION OF PHOSPHOLEMMAN
MIMICS EFFECTS OF CARDIAC GLYCOSIDES
ON ISOLATED CARDIOMYOCYTES

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

PROGRAM OF CELL AND MOLECULAR PHYSIOLOGY

BY
RYAN D. HIMES
CHICAGO, IL
AUGUST 2015

Copyright by Ryan D. Himes, 2015
All Rights Reserved

ACKNOWLEDGEMENTS
This work would not have been possible without the help of many people.
My advisor, Dr. Seth Robia, helped me every step of the way. He and I conceived of
the project idea together, and he spent countless hours training me in the
techniques that I used, the data analysis, the presenting of data and the writing
process. I greatly appreciated his patience with me, and his willingness to take time
out of whatever he was working on at the time to answer my questions and provide
assistance.
All of my lab colleagues deserve thanks for their support as well. In
particular, Dr. Neha Abrol taught me how to perform functional myocyte assays, Dan
Blackwell helped with cell culture and molecular cloning, and former technicians
Alex Ticho and Chris Stefonowicz helped make some of the constructs used for this
work.
I also want to thank all of my committee members: Dr. Allen Samarel
(chairman), Dr. Sakthivel Sadayappan, Dr. Ken Byron, Dr. Jack Kaplan, and former
members Dr. Renzhi Han and Dr. Graeme Carnegie.

ii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS

ii

LIST OF FIGURES

vi

LIST OF ABBREVIATIONS

vi

ABSTRACT

vii

CHAPTER ONE: HEART FAILURE, PLM, AND NKA

1

CHAPTER TWO: METHODS

18

CHAPTER THREE: RESULTS OF FRET AND FUNCTIONAL ASSAYS

27

CHAPTER FOUR: POTENTIAL THERAPEUTICS FOR HEART FAILURE

55

BIBLIOGRAPHY

62

VITA

71

iii

LIST OF FIGURES
Figure

Page

1. Mechanism of action of cardiac glycosides

14

2. Regulation of NKA activity

15

3. PLM binding equilibria

16

4. Fluorescently-labeled PLM and NKA

17

5. Fluorescent images of HEK cells

37

6. Effect of masking on images

38

7. Effect of masking on FRET data

39

8. PLM-NKA and PLM-PLM binding curves

40

9. KD values for PLM mutants

41

10. Fitting parameters for all binding curves

42

11. KD2 versus KD1 for each PLM mutant compared to WT

43

12. SBFI-based NKA activity assay

44

13. Ideal NKA activity curve derived from SBFI assay

45

14. Typical NKA activity curve derived from SBFI assay

46

15. Ouabain-sensitive ATPase activity of membrane preparations

47

16. Exogenous expression of PLM-Citrine in a myocyte

48

17. Examples of myocyte assay output

49

18. Functional myocyte data for WT PLM versus GFP

50

iv

19. Functional effects of PLM mutants in myocytes

51

20. WT- versus L30A-expressing myocytes in the presence of isoproterenol

52

21. Ca2+ transient data for WT versus L30A-expressing myocytes

53

22. Myocyte contraction data for WT versus L30A-expressing myocytes

54

23. Pharmacological versus physiological inhibition of NKA

61

v

LIST OF ABBREVIATIONS
Ax594

Alexa Fluor 594

ECFP

enhanced cyan fluorescent protein

FRET

fluorescence resonance energy transfer

FWHM

full width at half maximum

GFP

green fluorescent protein

HEK

human embryonic kidney

HF

heart failure

NCX

sodium-calcium exchanger

NKA

sodium-potassium ATPase

PBS

phosphate buffered saline

PLB

phospholamban

PLM

phospholemman

SBFI

sodium-binding benzofuran isophthalate

SERCA

sarco/endoplasmic reticulum Ca2+-ATPase

SR

sarcoplasmic reticulum

TM

transmembrane

WGA

wheat germ agglutinin

WT

wild-type

vi

ABSTRACT
In order to determine if mutations made to phospholemman (PLM) could
increase PLM binding to the Na/K-ATPase (NKA) and cause positive inotropy we
performed scanning mutagenesis of the transmembrane domain of PLM and
measured FRET between each mutant and NKA. We observed increased binding to
NKA for several PLM mutants compared to WT, including L27A, L30A, and I32A. In
isolated cardiomyocytes, overexpression of WT PLM increased the amplitude of the
Ca2+ transient compared to GFP control. Ca2+ transient amplitude was further
increased by L30A PLM overexpression. L30A mutation also delayed Ca2+ extrusion
and increased the duration of the cardiomyocyte contraction. This mimics aspects
of the effect of cardiac glycosides, which are known to increase contractility through
inhibition of NKA. No significant differences between WT and L30A PLM
overexpression were observed after treatment with isoproterenol, suggesting that
the effects of L30A are reversible with β-adrenergic stimulation. The results
implicate L30 as an important functional determinant and suggest that expression
of L30A PLM could increase cardiac contractility while providing physiological
reversibility of NKA inhibition.
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CHAPTER ONE
HEART FAILURE, PLM, AND NKA
The heart plays a critical role in human physiology. It is the pump that
provides blood flow to every cell in the body. The blood carries oxygen and
nutrients to the cells, and also provides a means for cells to eliminate waste
products and carbon dioxide. Without this constant perfusion of blood, cells and
tissues die rapidly (Bers, 2002; McMurray & Pfeffer, 2005; Mudd & Kass, 2008).
When the heart is not pumping properly and blood flow is insufficient to meet the
demands of the body, the condition is known as heart failure (HF) (McMurray &
Pfeffer, 2005; Mozaffarian et al., 2015; Mudd & Kass, 2008). This is one of the
leading causes of morbidity and mortality around the world (McMurray & Pfeffer,
2005; Mozaffarian et al., 2015).
The four main causes of HF are myocardial infarction (heart attack), defects
with the valves of the heart, hypertension, and cardiomyopathies (diseases of the
heart muscle) (McMurray & Pfeffer, 2005; Mozaffarian et al., 2015). These
conditions can either cause a weakening of the contraction strength of the heart
(systolic HF), or a decrease in the ability of the heart to fill with blood between
contractions (diastolic HF). Both types of HF can lead to symptoms such as fatigue,
as well as pulmonary and peripheral edema. These symptoms can all contribute to
the worsening of the HF condition, thus forming a dangerous “positive feedback
1
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loop” where the disease gets progressively worse over time. Without successful
intervention, HF will result in death. Indeed, the disease is attributed as the
underlying cause of death in nearly 60,000 cases per year in the US alone (Fuller et
al., 2012; Hauptman & Kelly, 1999; Mozaffarian et al., 2015; Yang, Shah, & Criley,
2012).
There are various therapies available to treat HF. The oldest type of
treatment is the class of drugs known as cardiac glycosides, which have been used
for centuries (Bers, 2002; Fuller et al., 2012; Hauptman & Kelly, 1999; Yang et al.,
2012). Although their mechanism of action was unknown at first, now it is known
that these drugs bind to and inhibit the action of the Na/K-ATPase (NKA) in heart
muscle (Figure 1). NKA is responsible for extruding sodium from the cell after the
propagation of the action potential (the electrical signal that travels throughout the
heart and causes it to contract). Each action potential causes sodium to enter the
cells, and NKA must rapidly pump the sodium back out again before the next action
potential arrives (Bers, 2002; Lingrel, Argüello, Van Huysse, & Kuntzweiler, 1997).
When bound by cardiac glycoside, NKA is unable to extrude sodium, and so the
intracellular sodium concentration, [Na+]i, increases (see Figure 1) (Lingrel et al.,
1997; Philipson & Nicoll, 2000).
This rise in [Na+]i leads to the reduction of Ca2+ extrusion by the sodiumcalcium exchanger (NCX; Figure 1) (Philipson & Nicoll, 2000; Shattock et al., 2015).
NCX normally transports sodium ions into the cell in exchange for calcium from the
cytosol. However, when [Na+]i is elevated, this sodium-calcium exchange activity is
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reduced, leading to a rise in

[Ca2+]i.

NCX can even act in reverse when

[Na+]i

is very

high, transporting Ca2+ into the cell from the outside. Increased [Ca2+]i leads to an
increase in the strength of muscle cell contractions (also known as contractility)
(Hauptman & Kelly, 1999; Shattock et al., 2015; Yang et al., 2012). Therefore, by
inhibiting NKA activity and causing a rise in [Na+]i and [Ca2+]i, cardiac glycosides
increase cardiac contractility, which can relieve the condition of HF.
However, cardiac glycosides can also be harmful if administered at too high
of a dose (Hauptman & Kelly, 1999; Homma, Amran, Nagasawa, & Hashimoto, 2006;
Yang et al., 2012). Overdose of these drugs leads to overload of [Na+]i, and overload
of Ca2+ in the sarcoplasmic reticulum (SR), which is the main storage organelle for
Ca2+ in muscle. When the SR is overloaded, Ca2+ can leak out, causing cells to
contract at an inappropriate time. This is known as a delayed afterdepolarization,
and occurs as Ca2+ is extruded by NCX, generating a positive inward current that can
trigger another action potential throughout the heart. The outcome is often the
generation of a cardiac arrhythmia (Homma et al., 2006; Yang et al., 2012).
Arrhythmias compromise the ability of the heart to contract in a coordinated
fashion and to generate optimal ejection of blood from the heart. Therefore, if the
cardiac glycoside overdose is large enough to be arrhythmogenic, instead of
improving cardiac output and relieving HF, it will actually worsen the health of the
patient.
While every drug causes side effects and every drug has a limited range of
effective concentrations, the therapeutic window for cardiac glycosides is especially
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narrow (Yang et al., 2012). Patients who are taking these drugs have their blood
drawn sometimes on a daily basis to ensure that the drug concentration is high
enough to be beneficial, but not so high as to be arrhythmogenic. If an overdose is
administered, clearance from the blood is slow because the affinity of glycosides for
NKA is quite high, and also the half-life is quite long (the half-life of digoxin is 20-50
hours) (Bossuyt et al., 2009; Cheung et al., 2010; Crambert, Fuzesi, Garty, Karlish, &
Geering, 2002; Yang et al., 2012). Doctors can use an anti-glycoside antibody in this
case to help sequester the drug away from NKA and to aid in clearance. Because of
their dangerously narrow therapeutic window, more and more physicians have
been turning away from cardiac glycosides and are looking toward other options for
treating HF, such as vasodilators which reduce cardiac afterload by decreasing
systemic blood pressure.
I propose that a better way to treat HF may be to use a superinhibitory
mutant form of the protein phospholemman (PLM). This 15-kDa protein was
discovered to be an endogenous inhibitor of NKA in the heart in 2002 (Bossuyt et al.,
2009; Cheung et al., 2010; Crambert et al., 2002; Despa et al., 2005). If a mutation to
PLM causes it to bind to NKA with greater affinity than wild-type (WT) PLM, this
could increase cardiac contractility through the same mechanism of action of
cardiac glycosides, described above. However, the advantage to this approach for
treating HF is that the cell can dynamically regulate the interaction of PLM with NKA
by two physiological mechanisms.

5
First, while cardiac glycosides prevent NKA from transporting

Na+

out of the

cell, PLM reduces the affinity of NKA for Na+ (Despa et al., 2005). This is depicted in
Figure 2. Compared to the activity of NKA by itself, NKA bound by cardiac
glycosides has a reduced maximal activity, or Vmax. The degree to which glycosides
reduce the Vmax of NKA is dependent on the percentage of NKA molecules that are
bound by the drug, which is directly proportional to the drug concentration. More
drug causes a greater reduction in NKA activity, and a greater rise in [Na+]i and
[Ca2+]i. At any given [Na+]i, the activity of NKA is lower when the drug is applied
than when it is absent. In contrast, the effect of PLM is not to change the Vmax of
NKA, but to shift the K0.5, or the [Na+]i at which NKA activity is half of Vmax (Bossuyt
et al., 2009; Despa et al., 2005; Han, Tucker, Lingrel, Despa, & Bers, 2009). The K0.5
is inversely proportional to the affinity of NKA for Na+; that is, a lower K0.5 means
NKA has a greater affinity for Na+. PLM causes the K0.5 to increase, and the affinity of
NKA for Na+ to decrease. But PLM has little to no effect on Vmax (Bossuyt et al., 2009;
Despa et al., 2005; Han et al., 2009). Therefore, at high [Na+]i, inhibition of NKA by
PLM is overcome, Na+ can be extruded, and Na+ overload (and indirectly, Ca2+
overload) can be avoided. I propose that a superinhibitory PLM mutant could be a
superior treatment for HF if it increases K0.5 more than WT PLM, without having an
effect on Vmax.
The second physiological mechanism by which the cell can relieve the
inhibition of NKA by PLM is by phosphorylating PLM through β-adrenergic signaling
(Despa et al., 2005; Han, Bossuyt, Martin, Despa, & Bers, 2010). When the body is
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stressed, as in a fight-or-flight situation, epinephrine and norepinephrine are
released into the bloodstream from the adrenal glands above the kidneys. These
bind to β-adrenergic receptors on the outside of the heart and causes PLM to be
phosphorylated through the signaling pathway of protein kinase A (Bossuyt, Despa,
Martin, & Bers, 2006; Despa et al., 2005; Han et al., 2010; Han, Bossuyt, Despa,
Tucker, & Bers, 2006; Khafaga et al., 2012). This causes relief of inhibition of NKA
by PLM (Boguslavskyi et al., 2014; Bossuyt et al., 2006; Han et al., 2006; Khafaga et
al., 2012; Q. Song, Pallikkuth, Bossuyt, Bers, & Robia, 2011; Wypijewski et al., 2013),
and this is also depicted in Figure 2. The K0.5 of NKA returns to the baseline value
when PLM is phosphorylated, meaning NKA is able to more rapidly extrude sodium
from the cell. This allows the heart to pump at a faster rate, enabling the individual
to respond quickly to the physical threat that has triggered the fight-or-flight
response. In the case of a superinhibitory PLM mutant, phosphorylation by PKA
could allow the inhibition of NKA to be relieved if [Na+]i or [Ca2+]i becomes too high,
assuming that the PLM mutant is still capable of being phosphorylated. Because of
the physiological means by which the cell limits the inhibition of NKA by PLM, I
predict that using a superinhibitory PLM mutant will be a superior treatment
strategy for HF compared to the pharmacological approach of using cardiac
glycosides.
It needs to be determined what mutation(s) of PLM will cause increased
inhibition of NKA. I theorize that single alanine substitutions of PLM
transmembrane domain residues would yield one or more superinhibitory mutants.
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The rationale behind this theory is based on the knowledge that monomeric PLM
can either bind to NKA, or it can bind to itself and form homotetramers (see Figure
3) (Bers, 2002; Boguslavskyi et al., 2014; McMurray & Pfeffer, 2005; Mudd & Kass,
2008; Q. Song et al., 2011; Wypijewski et al., 2013). There two binding equilibria are
linked, as PLM phosphorylation causes decreased binding of PLM to NKA and
increased binding of PLM to PLM in tetramers (Beevers & Kukol, 2006; 2007;
McMurray & Pfeffer, 2005; Mozaffarian et al., 2015; Mudd & Kass, 2008; Q. Song et
al., 2011). It is plausible, therefore, that a mutation that decreases PLM-PLM
binding would increase the availability of free PLM monomer to bind to NKA. It is
thought that the transmembrane domains of PLM mediate PLM-PLM binding
(Beevers & Kukol, 2006; 2007; McMurray & Pfeffer, 2005; Mozaffarian et al., 2015;
Palmer, Scott, & Jones, 1991). There are several leucine and isoleucine residues in
this domain that could mediate binding with the formation of leucine/isoleucine
zippers (Cheung et al., 2010; McMurray & Pfeffer, 2005; Mozaffarian et al., 2015;
Palmer et al., 1991). Mutation of these residues to the smaller residue alanine could
disrupt PLM tetramerization, and indirectly cause increased PLM-NKA binding,
which could lead to a superinhibitory effect. The other advantage to mutating the
transmembrane domain residues is that by leaving the residues of the cytosolic
domain intact, the site of PLM phosphorylation is left undisrupted. This makes it
likely that any candidate superinhibitory mutant would still be phosphorylatable,
and therefore the superinhibition would be reversible by this mechanism.
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There are twenty residues in the transmembrane domain of PLM (Bidwell,
Blackwell, Hou, Zima, & Robia, 2011; Cheung et al., 2010; Fuller et al., 2012;
Hauptman & Kelly, 1999; Hou, Kelly, & Robia, 2008; E. M. Kelly, Hou, Bossuyt, Bers,
& Robia, 2008; Mozaffarian et al., 2015; Palmer et al., 1991; Robia et al., 2007; Yang
et al., 2012). Residue 24 is an alanine, so there are nineteen remaining residues that
can be mutated to alanine and tested for superinhibitory potential. To screen these
nineteen candidates in a reasonable timeframe, my advisor and I developed a
fluorescence-based assay. Each PLM mutant was fused to the yellow fluorescent
protein Citrine on the C-terminus of PLM (see Figure 4). These constructs were
expressed (one at a time) in a cell line that stably expresses NKA tagged with
enhanced cyan fluorescent protein (ECFP) on the N-terminus. I measured
fluorescence resonance energy transfer (FRET) from ECFP to Citrine to quantify
PLM-NKA binding. In the same cells, I also measured homotransfer FRET from
Citrine to Citrine to quantify PLM-PLM binding. I hypothesized that PLM mutants
that caused decreased PLM-PLM binding would also cause increased PLM-NKA
binding. These mutants would be considered candidate superinhibitors and would
be tested for functional effects on NKA activity and muscle cell contractility in later
experiments. If a PLM mutant was found to be superinhibitory and to cause
increased contractility, it could have the potential to be used clinically as a superior
treatment for HF compared to cardiac glycosides.
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NKA and PLM: a review
In 1957, Jens Christian Skou discovered NKA, and for this work he received a
share of the Nobel Prize in Chemistry (Fuller et al., 2012; SKOU, 1957). NKA is
expressed in virtually every living organism (Fuller et al., 2012), and it hydrolyzes
ATP to provide the necessary energy to remove three sodium ions from the cytosol
in exchange for two potassium ions entering the cell. This has the net effect of
reducing one positive charge within the cell for every pump cycle. NKA is a member
of the P-type ATPase family, which is characterized by four structural domains
(transmembrane, actuator, nucleotide-binding, and phosphorylation domains) and a
phospho-enzyme intermediate state.
The affinity of NKA for Na+ has been estimated to range from 9 to 19 mM,
which is close to the resting [Na+]i in the heart (Fuller et al., 2012). However,
evidence suggests that NKA may be exposed to a sub-sarcolemmal pool of Na+ that
differs in concentration from bulk cytoplasmic Na+ (Silverman, Warley, Miller,
James, & Shattock, 2003). Therefore, other transporters of Na+ besides NKA (e.g.
NCX) likely play an important role in regulating NKA activity by influencing this subsarcolemmal pool of Na+ (Dostanic, Schultz, Lorenz, & Lingrel, 2004).
In cardiac (as well as vascular smooth muscle) the two predominant isoforms
of NKA are the α1 and α2 subunits, with α3 expression being relatively minor
(Shattock et al., 2015). In cardiac muscle, evidence suggests that the α2 isoform is
localized to the T-tubules, specifically near the junctional SR (Berry, Despa, Fuller,
Bers, & Shattock, 2007), whereas the α1 isoform is expressed throughout the
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sarcolemma. The functional implication of this is that the α2 subunit specifically
regulates junctional sodium, and therefore calcium, and that this contributes to the
regulation of muscle contraction. Indeed, evidence suggests that α2 in the heart is
functionally coupled to NCX (P. F. James et al., 1999). However, α1 still influences
cardiac excitation-contraction coupling as a global regulator of [Na+]i (Fuller et al.,
2012). There are also three different isoforms of NKA β subunits. These serve to
help in trafficking of the α subunit to the plasma membrane (Fuller et al., 2012). In
cardiac muscle, the principal β isoform is β1, although β3 is also present (Tulloch et
al., 2011). The principle FXYD protein expressed in the heart is PLM, although
FXYD5 has also been detected in homogenates of whole hearts (Lubarski, PihakaskiMaunsbach, Karlish, Maunsbach, & Garty, 2005).
PLM regulates both the α1 and α2 isoforms. Unphosphorylated PLM exerts
tonic inhibition on the pump, and phosphorylation relieves this inhibition; however,
phosphorylation does not completely abolish PLM-NKA binding (Bossuyt et al.,
2006). It is not currently clear how PKA and PKC activity differentially influence α1
versus α2 activity. Inhibition of NKA alpha subunits is also mediated by posttranslational modifications. Palmitoylation and glutathionylation in response to
oxidative stress result in inhibition of pump activity (Figtree et al., 2009; Howie,
Tulloch, Shattock, & Fuller, 2013).
For normal cardiac function, the trans-sarcolemmal sodium gradient must be
maintained. But in the context of HF, [Na+]i has been shown to be elevated, and this
is at least partially attributable to impaired NKA function and/or reduced NKA
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expression (Pogwizd, Sipido, Verdonck, & Bers, 2003). Impaired NKA function may
be due to the fact that PLM is hypophosphorylated in HF, which has been shown to
contribute to worsening pathology (Boguslavskyi et al., 2014).
PLM was initially discovered in 1985 by Larry Jones and co-workers (Presti,
Jones, & Lindemann, 1985a). They showed that it is localized to the sarcolemma,
and that it is phosphorylated in response to isoproterenol. Subsequent studies
showed that it is also phosphorylated by PKC (Presti, Scott, & Jones, 1985b) and that
it is dephosphorylated by PP1 and PP2a (Neumann et al., 1999). In 1991, the
protein was purified and its primary amino acid sequence was determined (Palmer
et al., 1991). PLM is synthesized as a 92 residue pro-peptide, but the first 20 amino
acids are then cleaved off, leaving a mature, 72 amino acid protein (Cheung et al.,
2010). This has three domains: an N-terminal extracellular domain (which contains
the FXYD motif), a transmembrane domain, and a C-terminal cytosolic domain, each
of which are composed of α-helices (Cheung et al., 2010). Various estimates put the
basal phosophorylation of PLM at 25 – 46% (Fuller et al., 2009; Silverman et al.,
2005; Zhang et al., 2009).
In the year 2000, Kathy Sweadner found that PLM is a member of a larger
family of FXYD proteins (Sweadner & Rael, 2000). There are at least 12 members of
this family of proteins, all of which contain an extracellular FXYD motif, a single
transmembrane domain, and which regulate ion transport (Cheung et al., 2010).
FXYD2 (also known as the gamma subunit of NKA) is expressed in the kidney
(Sweadner & Rael, 2000), and FXYD5 is present in HEK cells (Arystarkhova, Donnet,

12
Muñoz-Matta, Specht, & Sweadner, 2007). PLM is unique among the FXYD proteins,
however, because of its conserved phosphorylation sites in the cytosolic domain
(Fuller et al., 2012). It was originally proposed that these FXYD proteins
oligomerized to form anion channels and to regulate cell volume (Moorman et al.,
1995). But while subsequent studies proved that PLM does indeed form oligomers
(Beevers & Kukol, 2006; 2007; Bossuyt et al., 2006; 2009; Q. Song et al., 2011),
various laboratories have failed to demonstrate an ion channel function for these
oligomers (Fuller et al., 2012).
In 2002, Kaethi Geering showed for the first time that PLM coimmunoprecipitates with NKA α subunits (Crambert et al., 2002). NMR and X-ray
crystallography suggest that the TM domain of FXYD proteins interacts with TM
helices 2, 6 and 9 of NKA α subunits (Li et al., 2004; Lindzen, Gottschalk, Fuzesi,
Garty, & Karlish, 2006). It was later shown that PLM reduces the affinity of NKA for
Na+ and K+, while only minimally reducing Vmax (Crambert et al., 2002).
Phosphorylation of PLM reverses these effects on NKA, allowing the heart to
maintain the trans-sarcolemmal Na+ gradient during sympathetic stimulation,
thereby preventing Na+ and Ca2+ overload and arrhythmogenesis (Despa, Tucker, &
Bers, 2008).
Phosphorylation of PLM has also been shown to cause inhibition of Ca2+
extrusion by NCX (Ahlers et al., 2005; Cheung et al., 2007; J. Song et al., 2012; J.
Wang et al., 2006; Zhang et al., 2006). This is thought to help preserve inotropy
while maintaining the trans-sarcolemmal Na+ gradient during sympathetic
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stimulation (Cheung et al., 2010). However, another laboratory failed to detect a
direct PLM-NCX interaction with co-immunoprecipitation or FRET (Bossuyt et al.,
2006) so this theory has yet to gain broad acceptance in the field.
PLM has also been shown to interact with L-type Ca2+ channels in guinea pig
myocytes and to alter their gating in HEK cells (X. Wang et al., 2010). PLM
decreased the kinetics of activation and deactivation of these channels, and also
increased the rate of voltage-dependent inactivation. In these studies, the FXYD
motif was found to mediate these effects (Guo et al., 2010). However, whether PLM
plays this role in the heart or if these observations were simply due to
overexpression of PLM in HEK cells remains to be tested (Fuller et al., 2012).
In addition to being phosphorylated, PLM can also be palmitoylated at its two
cytosolic cysteine residues, C40 and C42 resulting in inhibition of NKA (Tulloch et
al., 2011). These cysteines are well conserved, both among FXYD family members
and across species (Cornelius & Mahmmoud, 2003; Fuller et al., 2012). Therefore,
palmitoylation may be a mechanism of regulation of NKA in tissues other than the
heart.
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Figure 1. Mechanism of action of cardiac glycosides. Cardiac glycosides bind to
and inhibit the action of NKA, resulting in a rise in [Na+]i. This inhibits the action
of NCX, leading to a rise in [Ca2+]i and increased contractility. However,
overdoses of cardiac glycosides can lead to overload of Ca2+ in the SR, Ca2+ leak,
and arrhythmias.
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Figure 2. Regulation of NKA activity. The activity of NKA over a range of
concentrations of intracellular Na+ is depicted in black. The effect of cardiac
glycosides in shown in green. Glycosides reduce Vmax for NKA. In red, the
activity of NKA when bound by WT PLM is displayed, and the effect of PLM
phosphorylation by PKA or PKC is shown in blue. PLM reduces the affinity of
NKA for Na+, without changing Vmax. Phosphorylation of PLM reverses this
effect. The proposed regulation of NKA by a superinhibitory PLM mutant is
shown in orange. It is hypothesized here that superinhibitory PLM will reduce
the affinity of NKA for Na+ to a greater extent than WT PLM, but that Vmax will
remain unaffected.
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Figure 3. PLM binding equilibria. PLM monomer is capable of both binding to
itself to form homotetramers and binding to NKA to form the PLM-NKA
regulatory complex. Both of these complexes are thought to be in equilibrium
with PLM monomers.
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Figure 4. Fluorescently-labeled PLM and NKA. For the FRET assay in this study,
PLM mutants were covalently attached to Citrine (depicted in yellow) and NKA
was attached to ECFP (in light blue). Acceptor sensitization FRET was used to
quantify the affinity of each mutant for binding to NKA, which is inversely
proportional to KD2. Homotransfer FRET was used to quantify the affinity of
each mutant for binding to itself, which is inversely proportional to KD1.

CHAPTER TWO
METHODS
In this chapter, I will detail the FRET-based screening assay for the PLM
mutants, as well as the experiments used to measure the effects of PLM mutation on
NKA activity and on cardiomyocyte contractility.
Molecular biology and cell culture
In order to generate and screen PLM mutants for their superinhibitory
potential, first canine WT PLM-Citrine plasmid was obtained from collaborators at
the University of California, Davis: Drs. Julie Bossuyt and Donald Bers. This
construct has a 19 amino acid linker between the C-terminus of PLM and the Nterminus of Citrine (Bers, 2002; Bossuyt et al., 2006; Fuller et al., 2012; Hauptman &
Kelly, 1999; Yang et al., 2012). Individual alanine mutations of the nineteen
transmembrane domain residues were then made using site-directed mutagenesis.
These constructs were used to express the Citrine-tagged PLM mutants in a stable
NKA-ECFP cell line (Bers, 2002; Khafaga et al., 2012; Lingrel et al., 1997), and cells
expressing both constructs were used to measure FRET and to quantify the PLMPLM and PLM-NKA binding interactions (described below). It should be noted that
canine PLM differs from the human sequence in only four residues—three in the
extracellular domain, and one in the transmembrane domain (in canines, valine 22
is an isoleucine).
18
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In order to express the PLM mutants in cardiac myocytes for contractility
assays (described below) the constructs had to be inserted into adenoviruses, as
these provide the most efficient means of expressing exogenous genes in myocytes.
To accomplish this, the PLM-Citrine DNA was amplified using PCR and inserted into
pShuttle vectors using restriction enzymes BamHI & EcoRV. These vectors were
then integrated into the adenoviral genome by Dr. Jody Martin using the AdEasy kit
(Stratagene) (Abrol, de Tombe, & Robia, 2015; Bidwell et al., 2011; Hou et al., 2012;
Lingrel et al., 1997; Pallikkuth et al., 2013; Philipson & Nicoll, 2000). All DNA
sequences were verified by sequencing (ACGT, Inc.).
Transient transfection of stable ECFP-NKA cell line
HEK-293 cells stably expressing ECFP tagged to the N-terminus of rat α1
NKA were cultured in Dulbecco’s modified Eagle’s medium with 10% FBS until the
day prior to imaging. Then cells were transferred to 60 mm culture dishes at a
density of 250,000 cells per dish. 24 hours later, the cells were transfected with 1
μg of either WT PLM-Citrine, or one of the mutants. Transfection was performed
using Turbofect reagent (10 μL, ThermoFisher). The transfection solution was
mixed and allowed to incubate at room temperature for 15 minutes before it was
added to the cells.
Acceptor sensitization FRET and anisotropy measurements
Approximately 24 hours following transfection, the cells were trypsinized
and transferred to 4-well glass-bottom chambers (MatTek) at a density of 150,000
cells per well. The cells were incubated for 90 minutes at 37°C in DMEM with 10%
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FBS to allow them to adhere to the bottom of the wells. They were then washed two
times with PBS before imaging, followed by loading with 2 μg/mL wheat germ
agglutinin (WGA) Alexa Fluor 594. This fluorescently-tagged lectin binds to cellsurface glycoproteins, and allows for FRET to be quantified exclusively at the
plasma membrane of the cell, where the PLM-PLM and PLM-NKA binding
interactions are relevant (this is described in further detail below). WGA was
applied to the cells for three minutes, and then was washed three times with PBS.
Cells were imaged on a Nikon inverted microscope, using a 40X air objective.
An acceptor sensitization FRET technique was used to measure binding between
ECFP-NKA and each PLM-Citrine construct. For each acquisition field, a set of four
images was taken to capture the fluorescence of ECFP, Citrine, FRET, and WGA Alexa
Fluor 594, with exposure times of 2000, 50, 500, and 300 ms respectively. For the
ECFP, Citrine, and WGA images, the specific fluorophore was excited and its
emission was captured, whereas for the FRET image, ECFP was excited and Citrine
emission was captured. Then the stage was automatically shifted so that a new field
was in focus, and the imaging was repeated. In total, for each PLM construct 130
fields were imaged in rapid succession using automated stage movements. Focus on
the cells was maintained using a perfect focus system (Nikon).
After these first four images were acquired for each field, the stage was reset
back to the initial position, and image scanning was repeated, this time using
polarization filters in order to measure fluorescence anisotropy of PLM-Citrine to
quantify PLM-PLM binding. If the PLM-Citrine peptides are in close proximity in the
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membrane, homotransfer FRET can occur as one Citrine is excited and transfers
energy to a neighboring Citrine (Blackman, Piston, & Beth, 1998; Philipson & Nicoll,
2000; Shattock et al., 2015). This energy transfer decreases the polarization of
emitted fluorescence, and the depolarization is quantified as a decrease in
fluorescence anisotropy. To measure the anisotropy of PLM-Citrine, vertically
polarized excitation light (wavelength = 504 nm) was used and then emission was
captured with either a vertical (Iparallel) or a horizontal (Iperpendicular) polarizing filter
in the emission light path. Both of these images were acquired with an exposure
time of 1000 ms.
For each field the WGA Alexa Fluor 594 image, which displayed fluorescence
only at the plasma membrane of each cell, was used to generate a “mask” that was
then applied to all other images. This was done using a no-neighbors deconvolution
algorithm (Metamorph) performed on the WGA images. Masks of just the plasma
membrane of each cell were then applied to all the other images in order to reduce
the contribution of any intracellular expression of fluorescent protein constructs.
This allowed us to calculate acceptor sensitization FRET and anisotropy solely at the
plasma membrane, where PLM-NKA binding is relevant.
For each cell, acceptor sensitization FRET was calculated according to the
formula:
FRET Efficiency (%) =
100 * (IFRET – aICitrine – dIECFP) / (IFRET – aICitrine –dIECFP + G*IECFP),
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where IFRET, ICitrine,, and IECFP are the average intensities of each cell in the FRET,
Citrine, and ECFP images, respectively, ‘a’ is the acceptor cross-talk coefficient, ‘d’ is
the donor bleed-through coefficient, and G is the ratio of sensitized emission to
donor emission for a standard FRET construct (donor linked to an acceptor
intramolecularly) (Hauptman & Kelly, 1999; Shattock et al., 2015; Yang et al., 2012;
Zal & Gascoigne, 2004). The acceptor cross-talk coefficient was measured by
imaging cells that only expressed Citrine (not ECFP), and then dividing the IFRET
values by the ICitrine values for those cells. Here it is crucial that the cells be imaged
with the exact same experimental conditions that are used for the actual
experiments. Similarly, the donor bleed-through coefficient was measured by
imaging cells that only expressed ECFP and dividing the IFRET values by the IECFP
values for those cells. G is measured by imaging cells expressing a donor-linked-toacceptor construct, in this case the blue fluorescent protein mCerulean linked to the
yellow fluorescent protein mVenus by a 5 amino acid linker. The cells are imaged
before and after destroying the mVenus with photobleaching, and G is calculated by
the formula G = (IFRET – aImVenus – dImCerulean) / (ImCerulean’ – ImCerulean), where ImCerulean’ is
the post-bleach ImCerulean. For the experiments performed in this manuscript, a =
0.091, d = 0.83, and G = 4.6.
Anisotropy was calculated according to the formula:
r = (Iparallel - Iperpendicular) / (Iparallel + 2Iperpendicular), where r is the average
anisotropy of each cell.
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Calculation of PLM-PLM and PLM-NKA binding affinities
Once the average acceptor sensitization and anisotropy for each cell was
calculated, these data were plotted against each cell’s PLM-Citrine expression as an
index of exogenous PLM concentration, in arbitrary units (Hauptman & Kelly, 1999;
Homma et al., 2006; Hou & Robia, 2010; Yang et al., 2012). These types of plots can
be used to quantify the binding affinity of a protein-protein interaction, because
FRET efficiency is proportional to the extent of binding of the proteins. By fitting
these plots with Hill functions, a dissociation constant (or KD) can be calculated for
each binding interaction in order to quantify the affinity. Lower KD values
correspond to greater affinity of binding. Here, the data were fit with the following
Hill functions.
For acceptor sensitization FRET:
FRET Efficiency (%) = c+((FRETmax-c)*[Protein]n) / (KD2n + [Protein]n),
where c is the FRET of the unbound fluorescent proteins, and FRETmax is the FRET
of the fully bound regulatory complex; n is the Hill coefficient, and [Protein] is the
average intensity of the Citrine for each cell in arbitrary units, taken to be an index
of the concentration of PLM. KD2 is the dissociation constant for the PLM-NKA
binding interaction.
For anisotropy:
Anisotropy (r) = r0+((rn-r0)*[Protein]n) / (KD1n + [Protein]n), where n is the
Hill coefficient, r0 is the inherent anisotropy of unbound fluorescent proteins, and rn
is the anisotropy of the fully bound PLM tetramer. KD1 is the dissociation constant
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for the PLM homotetramer. Fitting was performed with Origin software. For each
mutant PLM, four separate binding curves from four different transfections were
globally fit together, sharing all parameters except for KD. These four pairs of KD
values were then averaged together and plotted with their associated SEM.
Myocyte cell culture and functional assays
In order to test the effect of PLM mutations on cardiac function, mutants
were expressed in isolated rabbit ventricular myocytes. The rabbit PLM sequence is
>95% identical to the canine sequence, and there is precedence for using exogenous
canine proteins in isolated rabbit myocytes (Abrol et al., 2015; Homma et al., 2006;
Yang et al., 2012). Fusing these mutants to Citrine did not interfere with localization
of the exogenous proteins to the sarcolemma and T-tubules, as is shown in the next
section (Figure 16). These myocytes were isolated by Jollyn Tyryfter as described in
published literature (Domeier, Blatter, & Zima, 2009; Yang et al., 2012). Once
isolated, cells were pipetted into a 50 mL conical tube and allowed to settle for 5-10
minutes until pelleted. The supernatant was drawn off, and then the cells were
reconstituted in 5 mL of PC-1 medium (Lotran, Inc.). This was repeated two more
times. Then cells were transferred to laminin-coated 14 mm cover slips (MatTek)
and incubated for one hour. Adenoviruses containing the DNA sequences for the
WT or mutant PLM-Citrine constructs were added to the cells at a multiplicity of
infection of 500 virus particles per cell (Bossuyt et al., 2009; Cheung et al., 2010;
Crambert et al., 2002; Pallikkuth et al., 2013; Yang et al., 2012). Dish volumes were
brought up to 2 mL with PC-1 medium and cells were incubated and paced at 10V, 5
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ms pulse duration, 0.1 Hz overnight (Bossuyt et al., 2009; Cheung et al., 2010;
Crambert et al., 2002; Despa et al., 2005; Pallikkuth et al., 2013). Pacing was
performed so that the T-tubules would remain intact throughout the culture period.
Effects of PLM mutants were compared to WT, which was used consistently as a
control throughout the experiments. That is, on any given experimental day, cells
isolated from a single rabbit were split into two groups, and one group was infected
with WT virus, while the other group was infected with a PLM mutant.
After ~18 hours of incubation cells were visualized using confocal
microscopy in order to observe the expression and localization of the PLM-Citrine.
Then, the cells were washed twice with Tyrode solution and were loaded with 10
μM Indo-1 AM for 20 minutes. This Ca2+-binding dye acts as an index of [Ca2+]i, as its
fluorescence intensity ratio increases with increasing [Ca2+]i (Molecular Devices).
The ratio is calculated by exciting the dye at λ = 340 nm and measuring emission at λ
= 405 and dividing by emission at λ = 485 nm. Finally, cells were washed three
times with Tyrode solution, and measurements were made with cells in the
presence of either Tyrode solution alone, or 20 nM isoproterenol in Tyrode solution.
20 nM isoproterenol was used because a higher concentration of 100 nM (Abrol et
al., 2015; Despa et al., 2005) caused the vast majority of myocytes to contract in a
dysrhythmic fashion. The ED50 of isoproterenol on β-adrenergic receptors is
approximately 50 nM (Bossuyt et al., 2009; Despa et al., 2005; Han et al., 2009; J. R.
Miller, Silver, & Stull, 1983; Y. Takuwa, Takuwa, & Rasmussen, 1988).
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Myocytes were stimulated to contract using 30 V, 2 ms duration pulses, and
0.5 Hz frequency (Bossuyt et al., 2009; Despa et al., 2005; Han et al., 2009; Pallikkuth
et al., 2013). Myoctes were measured only if they were not touching other cells,
were contracting longitudinally, and were adhered to the laminin-coated cover slip
in such a way that they could contract without coming off of the glass substrate.
Using an IonOptix system, the average length of the sarcomeres of each cell was
measured to quantify cell shortening (and contractility). This was done by drawing
a region of interest around a set of sarcomeres, approximately ten sarcomeres in
length, and one sarcomere wide. Sarcomeres were identified visually by a clear
pattern of alternating light and dark “stripes” on the image of the myocyte. At the
same time, Indo-1 fluorescence was measured within a region of interest that was
drawn around the cell at rest. The fluorescence intensity ratio F was measured as
described above, and was normalized to F0, the ratio at time = 0 sec. Ten
contractions were measured for each myocyte, and the resulting traces were
averaged together and fit using IonOptix software. I was blinded to the identity of
the myocyte samples while making measurements.
Statistics
All data are plotted as mean ± SEM. All mutant data were compared to WT
using Student’s unpaired T-test, with significance being noted at p < 0.05.

CHAPTER THREE
RESULTS OF FRET AND FUNCTIONAL ASSAYS
In order to measure the effects of PLM mutations on PLM-PLM and PLM-NKA
binding, Citrine-tagged PLM mutants were transiently transfected into a stable cell
line expressing ECFP-NKA, and a combination of homotransfer and heterotransfer
FRET assays were performed on the cells. Figure 5 displays the typical fluorescence
that was observed for ECFP-NKA, PLM-Citrine, and the plasma membrane stain
WGA Alexa Fluor 594. All three of these images were acquired in the same exact
field. Comparing the NKA image to the WGA image, I observed that nearly 100% of
the cells expressed the exogenous NKA. Expression was mostly localized to the
plasma membrane, with some fluorescence also being observed in the perinuclear
region. The Citrine image shows that approximately 50% of the cells expressed the
exogenous PLM, and that these cells also expressed the protein in the plasma
membrane and perinuclear region.
In contrast to the ECFP and Citrine fluorescence, the WGA Alexa Fluor 594
fluorescence was much more localized to the plasma membrane (i.e., there was very
little Alexa Fluor 594 fluorescence observed within the interior of the cell). Because
of this, the WGA images could be used to generate a plasma membrane mask that
was applied to all the other images in each field. Then, the image analysis software
(Metamorph) could quantify the fluorescence underneath the mask for each cell. In
27
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Figure 6, the effect of masking is observed on an ECFP image of a cell. With masking,
the contribution of the perinuclear fluorescence to the overall measured
fluorescence in the cell is reduced. This allowed for the calculation of FRET in the
area of the cell where the PLM and NKA binding interactions are most relevant.
For each PLM mutant, many transfected cells were imaged, and the average
acceptor sensitization FRET at the plasma membrane was calculated. These values
were plotted against the average Citrine intensity of each cell, which was used as an
index of the concentration of PLM. A representative graph is displayed in Figure 7,
before and after the WGA mask was used. Each of these data sets were fit with the
Hill function described in the previous chapter. Figure 7 shows that the WGA mask
reduced the variability in the data, and the correlation coefficient for the fit
improved from 0.61 to 0.78.
The same cells that were imaged to measure PLM-NKA binding (using the
acceptor sensitization FRET assay) were also imaged to measure PLM-PLM binding
(using the anisotropy assay). The average anisotropy at the plasma membrane of
each cell was plotted against the average Citrine intensity. A pair of PLM-NKA and
PLM-PLM binding graphs for WT PLM are shown in Figure 8.
In order to calculate the KD1 and KD2 values for each PLM mutant, data from
four separate biological replicates (transfections) were generated. Each biological
replicate yielded a pair of anisotropy and acceptor sensitization binding curves.
These were then globally fit using Origin software and the Hill functions described
in the previous chapter. For anisotropy curves, all of the fitting parameters were
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shared for each mutant, except for the KD1 parameter. That is, the four binding
curves from the four biological replicates were fit together using global fitting,
assuming that the r0, rn, and Hill coefficients were the same among the four
replicates, but allowing KD1 to vary. This allowed for the measurement of the
variance in KD1 among biological replicates. Similarly, for acceptor sensitization
curves, all of the fitting parameters where shared for each mutant, except for the
KD2 parameter. The average KD values ± SEM for each mutant are shown in Figure
9. The fitting parameters are displayed in Figure 10.
Figure 9 compares the KD values for each PLM mutant to WT (and a blue
dashed line has been drawn for reference). For KD1, mutants that had lower values
than WT are considered more tetrameric, because KD values are inversely
proportional to the affinity of binding. The first mutant displayed after WT is the
phosphomimetic S63E/S68E PLM, which was found to be significantly more
oligomeric than WT. This is in agreement with previous results from the Robia lab
and other groups which showed that PLM phosphorylation increases
tetramerization (Boguslavskyi et al., 2014; Despa et al., 2005; Han et al., 2010; Q.
Song et al., 2011; Wypijewski et al., 2013). In contrast, non-phosphorylatable
mutant S63A/S68A was more oligomeric than the phosphomimetic, and was not
significantly different from WT. All of the transmembrane domain alanine
substitution mutants displayed robust homotransfer FRET. While the KD1 values of
several mutants were not significantly different from WT, five mutants (I18A, I23A,
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I26A, G31A and L33A) were significantly more oligomeric. One mutant, L30A, was
less oligomeric, with a KD1 value approximately four-fold greater than WT.
In Figure 9, mutants with KD2 values less than WT are considered gain of
NKA binding mutants; those with values greater than WT are loss of binding. I
observed significantly increased PLM-NKA binding for non-phosphorylatable PLM.
Phosphomimetic PLM displayed decreased affinity for NKA binding, and this
approached statistical significance (p = 0.067). These results were as predicted
based on previous studies (Bossuyt et al., 2006; Despa et al., 2005; Han et al., 2006;
2010; Khafaga et al., 2012; Q. Song et al., 2011). These previous studies had led me
to hypothesize that KD2 was dependent on KD1. That is, PLM modifications that
increased KD1 would also decrease KD2, and vice versa. However, while this
relationship was true for phosphomimetic and non-phosphorylatable PLM, it was
not true for most of the transmembrane domain mutants. Instead, many of the
mutants (I23A through S37A) displayed increased PLM-NKA binding regardless of
the effect on oligomerization. I22A was the only mutant that had a significantly
increased KD2 compared to WT.
Figure 11 displays these same KD1 values on the x-axis, and KD2 values on the
y-axis, ± SEM. As mentioned above, no clear dependence of KD2 on KD1 is observed.
This is in contrast to what was observed for another membrane transporter, SERCA,
and its small peptide regulator, PLB (Boguslavskyi et al., 2014; Bossuyt et al., 2006;
Han et al., 2006; Khafaga et al., 2012; Kimura, Kurzydlowski, Tada, & MacLennan,
1997; Q. Song et al., 2011; Wypijewski et al., 2013). Indeed, it was these findings
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from SERCA/PLB, along with the results of studies on PLM phosphorylation, that
contributed to the hypothesis that the dependence of KD2 on KD1 would be true for
transmembrane domain PLM mutants as well. The only mutant for which that was
the case was L30A, which had an increased KD1 value and a decreased KD2. Still, the
main goal of this study was to find superinhibitory PLM mutants, and all of the
mutants that displayed increased PLM-NKA binding were considered candidate
superinhibitors. Several of these mutants were tested for functional effects on NKA
activity and myocyte contractility. I chose mutants L27A, L30A, and I32A, because
these showed some of the largest gains in NKA binding affinity.
PLM mutants that displayed increased NKA binding were hypothesized to
also cause increased NKA inhibition. This hypothesis was tested using several
different assays of NKA activity. However, none of them ended up being successful.
The first assay that was attempted involved the use of the sodium binding
fluorescent dye SBFI to measure [Na+]i (Despa, Islam, Pogwizd, & Bers, 2002;
Khafaga et al., 2012). As with the FRET assays, HEK cells expressing ECFP-NKA
were transiently transfected with PLM-Citrine mutants, and then were loaded with
SBFI. The fluorescence ratio of SBFI was monitored while cells were loaded with
Na+ using an external solution without K+. Without K+ as a counter-ion, NKA is
unable to maintain the Na+ gradient across the cell membrane, and so internal [Na+]
gradually equilibrates with external [Na+]. Then, the external solution is rapidly
switched to a 4 mM K+ solution without Na+, activating NKA and causing [Na+]i to
rapidly decline. Finally, the cells are brought to known concentrations of [Na+]i
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using standard solutions in order to calibrate the SBFI fluorescence to

[Na+]i.

An

example of one of these experiments is shown in Figure 12. In order to calculate
NKA activity over a range of [Na+]i values, the negative of the derivative of the Na+
extrusion portion of the data is calculated, and plotted against the [Na+]i value of
each point. A graph of this type is displayed in Figure 13, fit with a Hill function as
described in Chapter Two.
The problem with this assay was that the data were usually far more variable
than the examples shown in Figures 12 and 13, which were from the experiments
with the least amount of variability. Usually, the activity curves that were generated
failed to show a saturation of NKA activity. See Figure 14 for a more representative
example. Without saturation, it is difficult to measure the effects of PLM mutations
on NKA activity, as it is impossible to calculate Vmax or the affinity of NKA for Na+.
I also tried replacing SBFI with another dye that was purported to yield more
consistent results, Asante Natrium Green (TefLabs). However, the fluorescence
spectra of this dye overlap greatly with the spectra of Citrine (the peak excitation
wavelength for Asante is 517 nm, versus 516 nm for Citrine). Since my PLM
mutants were all tagged to Citrine, the signal to noise ratio of Asante fluorescence
was very low, making these experiments even more variable than the previous ones.
Lastly, I attempted to measure the ouabain-sensitive ATPase activity of
membranes from cells overexpressing the PLM mutants (this experiment was
performed in conjunction with Rebecca Clifford from the laboratory of Dr. Jack
Kaplan at the University of Illinois at Chicago). Ouabain, a cardiac glycoside, inhibits
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NKA activity (Laursen, Gregersen, Yatime, Nissen, & Fedosova, 2015; Lingrel et al.,
1997). Therefore by measuring the total ATPase activity at baseline and then
subtracting the activity measured in the presence of saturating ouabain, the NKAspecific ATPase activity can be calculated (Ishizuka, Fielding, & Berlin, 1996). To
test the viability of the experiment, I transfected HEK cells with either WT PLMCitrine, or untagged GFP as a control. The cells overexpressing PLM-Citrine
displayed fluorescence at the plasma membrane, while the GFP cells displayed
fluorescence throughout the cytoplasm. This fluorescence was even observable by
the naked eye after the membranes were isolated: for the PLM-overexpressing cells,
only the membrane fraction was fluorescent, while for the GFP-overexpressing cells,
only the cytosolic fraction was fluorescent. These qualitative observations
confirmed that the membrane preparation procedure worked properly.
However, when testing the membranes for ouabain-sensitive ATPase activity,
again a great deal of variability was observed. This is seen in Figure 15.
Furthermore, no significant difference was detected between PLM overexpression
versus the GFP control. This made it unlikely that subtle shifts in the Na+-binding
affinity of NKA due to PLM mutations would be resolvable using this assay.
It was at this point that I decided to abandon attempts at directly measuring
NKA activity, and moved on to testing for functional effects of PLM mutants on
cardiomyocytes. Cardiomyocytes isolated from rabbits were cultured and infected
with adenoviruses to overexpress WT or mutant PLM-Citrine. WT PLM was used as
a control each day that infections were performed, so as to be able to compare all
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other mutants to WT using cells isolated from a single rabbit (i.e., one rabbit was
used for each experimental day, and cells from that rabbit were infected with
separately infected with WT and a mutant form of PLM). After 24 hours of exposure
to virus, exogenous PLM expression was observed using confocal microscopy, as
shown in Figure 16. The WGA Alexa Fluor 594 stain was used here to label the
plasma membrane of the cardiomyocytes. As with expression in the HEK cell line,
Citrine fluorescence was observed in the perinuclear region as well as in the
sarcolemma and transverse tubulues where it co-localized with WGA.
After observing the expression and localization of the exogenous PLM
constructs, the cardiomyocytes were electrically paced. Both [Ca2+]i and its effect on
sarcomere shortening were measured simultaneously in cells overexpressing either
untethered GFP (control), WT PLM, or a mutant form of PLM. I was blinded to the
sample identity for these experiments. An example of the output is shown in Figure
17. Each electrical stimulus caused a rapid influx of Ca2+ and shortening of the
sarcomeres, followed by extrusion of calcium and cell relaxation. Approximately 10
stimuli were measured and then averaged together for each cell.
Figure 18 displays the average [Ca2+]i and sarcomere length traces for GFPvs. WT PLM-overexpressing myocytes. I observed a significant increase in the
amplitude of the Ca2+ transient for WT PLM compared to the control, as well as
significantly delayed kinetics of Ca2+ handling. These results were similar to what
was previously observed when treating isolated rabbit cardiomyocytes with
ouabain (a cardiac glycoside) in culture (Altamirano et al., 2006; Bers, 1987; 2002;
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Bers & Bridge, 1988). This suggests that NKA in these myocytes is not saturated by
endogenous PLM, and that overexpression of WT PLM in these cells is increasing
PLM-NKA binding. Furthermore, this increased binding possibly causes increased
inhibition of NKA activity, as the observed phenotype mimicked that of a known
NKA inhibitor.
Next, I compared the effects of the PLM mutants L27A, L30A, and I32A to WT.
Again, WT was used for comparison because it was tested on every single
experimental day, so that mutants could be compared to WT using cells isolated
from the same rabbit. While L27A and I32A displayed no significant effects on Ca2+
handling or cell shortening, L30A caused a significant increase in the amplitude of
the Ca2+ transient, as well as in the kinetics of Ca2+ handling and cell shortening. The
effects of L30A were significantly greater in magnitude than the effects of WT PLM
overexpression (compared to the GFP control). This suggests that, as was observed
with the FRET assay, L30A PLM causes increased binding to NKA compared to WT,
and it is likely that this results in increased inhibition of NKA (although I was unable
to test that directly). These results are summarized in Figure 19.
Finally, I tested the effect of isoproterenol on the function of cardiomyocytes
overexpressing L30A versus WT PLM, to see whether they could respond to
adrenergic stress. Isoproterenol is structurally similar to epinephrine and is a βadrenergic receptor agonist., known to lead to protein kinase A phosphorylation of
many target proteins, including PLM (Bers, 2002). As expected, 20 nM
isoproterenol treatment resulted in large inotropic and lusitropic effects on all cells
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tested (see Figure 20). Interestingly, no differences between WT and L30Aoverexpressing cells could be observed after treatment with isoproterenol. The
broadening of the Ca2+ transient by L30A PLM was no longer apparent after βadrenergic stimulation.
All of the Ca2+ handling and cell shortening parameters for WT versus L30A
PLM are displayed in Figures 21 and 22.
The results of all experiments are discussed in the following chapter.
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Figure 5. Fluorescent images of HEK cells. The three images above were all
acquired in the same field. On the left, the fluorescence of cells that stably
express ECFP-NKA is shown in blue. These cells were transfected with PLM
mutants tagged to Citrine, shown in yellow in the middle panel. The cell
membranes were also stained with WGA Alexafluor 594, shown in red on the
right.
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Figure 6. Effect of masking on images. On the left, a typical HEK cell expressing
ECFP-NKA is displayed. Fluorescence can be observed in a plasma membrane
and perinuclear pattern. After applying the plasma membrane mask, generated
from the WGA Alexa Fluor 594 image, and performing the deconvolution
algorithm, the resulting image is shown in orange on the right. Compared to the
left, the intracellular fluorescence is greatly reduced after masking.
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Figure 7. Effect of masking on FRET data. The graphs above display the average
FRET efficiency from cells co-expressing ECFP-NKA and WT PLM-Citrine,
plotted against the average Citrine intensity of each cell as an index of PLM
concentration. Data are shown before (left) and after (right) the plasma
membrane mask was applied to the images. Data were fit with a Hill function,
and the resulting correlation coefficients are displayed.
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Figure 8. PLM-NKA and PLM-PLM binding curves. On the left, WT PLM-NKA
FRET is plotted against the average Citrine intensity of each cell, as an index of
PLM concentration. On the right, the average anisotropy of each cell is plotted
against the same. The data sets have been fit with Hill functions.
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Figure 9. KD values for PLM mutants. The KD1 values ± SEM (left) for each PLM
mutant are compared to WT (blue dashed line). Mutants with KD1 less than WT
are considered more oligomeric. KD2 values ± SEM are also compared to WT
(right), and mutants with KD2 values less than WT are considered gain of NKA
binding mutants. N ≥ 4 biological replicates. *p<0.05 compared to WT by
Student’s T-test.
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Figure 10. Fitting parameters for all binding curves. The complete set of all
fitting parameter values is displayed for each PLM mutant, ± SEM. N ≥ 4
biological replicates.
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Figure 11. KD2 versus KD1 for each PLM mutant compared to WT. The KD2
value for each mutant is plotted against its KD1 value, ± SEM. The blue and
purple dashed lines are used as a reference to WT PLM. Phosphomimetic and
non-phosphorylatable PLM are plotted in red. N ≥ 4 biological replicates.
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Figure 12. SBFI-based NKA activity assay. The fluorescence ratio of SBFI is used
as an index of [Na+]i over time. First, cells are loaded with Na+ and then NKA is
activated by adding K+ to the external bath solution. The fluorescence signal is
then calibrated using solutions of known [Na+]i (see right-hand portion of
figure).
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Figure 13. Ideal NKA activity curve derived from SBFI assay. The activity of
NKA is calculated by taking the negative of the first derivative of the Na+extrusion portion of the SBFI assay data, and plotting against [Na+]i. This curve
can then be fit with a Hill function in order to calculate the K0.5 value, or the
affinity of NKA for Na+.
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Figure 14. Typical NKA activity curve derived from SBFI assay. Oftentimes, the
activity curve derived from the SBFI assay failed to saturate. Without
saturation, the K0.5 cannot be calculated, and therefore the effect of PLM
mutants on the Na+ affinity of NKA is difficult to assess.
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Figure 15. Ouabain-sensitive ATPase activity of membrane preparations. In
order to measure NKA activity in HEK cells overexpressing WT PLM, ouabainsensitive ATPase activity was calculated over a range of Na+ concentrations and
was compared to cells expressing GFP as a control. While the activity increased
with increasing [Na+], there was no significant difference between WT PLM and
GFP at any [Na+].
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Figure 16. Exogenous expression of PLM-Citrine in a myocyte. A rabbit
ventricular myocyte was infected with adenovirus used to express PLM-Citrine.
The protein is synthesized in the SR and trafficked to the sarcolemma and Ttubules, as evidenced by co-localization with WGA Alexa Fluor 594.
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Figure 17. Examples of myocyte assay output. As the cardiomyocytes are
paced, [Ca2+]i is measured over time (top) and is displayed as the fluorescence
ratio of Indo-1 dye. Simultaneously, cell shortening is measured by calculating
the average sarcomere length over time (bottom). About 10 transients are
measured for each cell and then averaged together.
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Figure 18. Functional myocyte data for WT PLM versus GFP. Averaged Ca2+
transients for myocytes expressing WT PLM (black, top) versus GFP (red) are
plotted as the normalized fluorescence ratio of Indo-1 over time, ±SEM. The
corresponding myocyte contractions are displayed as averaged sarcomere
lengths over time, ±SEM (bottom). N ≥ 5 cells.
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Figure 19. Functional effects of PLM mutants in myocytes. Averaged Ca2+
transient amplitude (A), Ca2+ transient full width at half maximum (B), Ca2+
decay time constant (C), fractional shortening (D), full width at half maximum
for cell contractions (E), and cell relaxation time constant (F) ±SEM for GFP,
L27A, L30A, and I32A PLM normalized to WT (represented by a dashed line). *p
< 0.05 compared to WT. N ≥ 5 cells.

52

Figure 20. WT- versus L30A-expressing myocytes in the presence of
isoproterenol. Averaged Ca2+ transients for myocytes expressing WT PLM
(black, top) versus L30A (red) are plotted as the normalized fluorescence ratio
of Indo-1 over time, ±SEM. The corresponding myocyte contractions are
displayed as averaged sarcomere lengths over time, ±SEM (bottom). N = 38
cells from 4 different rabbits.
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Figure 21. Ca2+ transient data for WT versus L30A-expressing myocytes. Data
are displayed as means ± SEM. p-values from Student’s T-test are listed. N=38
cells from 4 different rabbits.
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Figure 22. Myocyte contraction data for WT versus L30A-expressing myocytes.
Data are displayed as means ± SEM. p-values from Student’s T-test are listed. N=38
cells from 4 different rabbits.

CHAPTER FOUR
POTENTIAL THERAPEUTICS FOR HEART FAILURE
The goal of these experiments was to test the hypothesis that alanine
substitution of PLM TM domain residues would destabilize PLM tetramers, leading
to increased PLM-NKA binding, increased inhibition of NKA activity, and increased
cardiac contractility that is reversible with β-adrenergic stimulation. This
hypothesis was based on several previous observations. First, Kimura et al.
demonstrated that alanine substitution of TM domain residues of PLB resulted in
decreased PLB oligomerization and increased binding to and inhibition of SERCA
(Kimura et al., 1997). Second, the Robia lab and others observed that
phosphorylation of PLM relieved inhibition of NKA and increased PLM
oligomerization (Bossuyt et al., 2006; Despa et al., 2005; Han et al., 2006; Q. Song et
al., 2011) (therefore it was plausible that decreasing PLM-PLM binding would lead
to increased PLM-NKA binding, and that this would be reversible with
phosphorylation). Third, cardiac glycosides are known to inhibit NKA, leading to a
positive inotropic effect (Bers, 2002; Hauptman & Kelly, 1999). The results shown
in the previous chapter, however, only partially support the hypothesis.
The anisotropy experiments demonstrated that for most of the TM domain
PLM residues, alanine substitution either had no effect, or caused increased PLMPLM binding (Figure 9). One mutant, L30A, did show a large decrease in PLM-PLM
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binding (increased KD1). This was matched by an increase in binding to NKA
(decreased KD2), as measured by acceptor sensitization FRET. But while L30A
conformed to the hypothesis, most of the other mutants did not. Surprisingly, many
showed increased PLM-NKA binding regardless of the effect on PLM oligomerization
(see Figure 9). This suggests that PLM oligomerization is not the sole determinant
of PLM-NKA binding. Shattock and co-workers reported the existence of a pool of
PLM that does not interact with NKA (Wypijewski et al., 2013). It is possible that
some of the mutants tested in my study are affecting the NKA-interacting and noninteracting pools of PLM separately. Further studies are needed to elucidate the
function of the NKA-independent pool and how PLM mutation affects that function.
Still, the goal of the FRET screen was to identify mutants that increased PLM-NKA
binding, and then to test those mutants for functional effects. I chose L27A, L30A,
and I32A as the initial candidates.
As described in the previous chapter, all attempts to measure the effect of
PLM mutation on NKA activity ultimately were unsuccessful. However, the
cardiomyocyte contractility and Ca2+ handling assay worked much better (in that it
yielded reproducible results). I observed that overexpression of WT PLM increased
the amplitude of the Ca2+ transient and increased the decay constant (tau) compared
to GFP control (Figure 19). This mimicked the effect of ouabain, a cardiac glycoside,
on isolated cardiomyocytes (Altamirano et al., 2006; Bers, 1987; 2002; Bers &
Bridge, 1988). While I did not observe an increase in fractional shortening, this is
possibly due to the fact that the myocytes were unloaded, and so increased
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contractility manifested as an increase in the duration of the contraction, rather
than an increase in shortening.
The fact that we observed these changes with WT PLM overexpression
suggests that in rabbits, NKA is not saturated by endogenous PLM binding. In
contrast, PLB-overexpressing rabbits had no observable phenotype, indicating that
SERCA is likely saturated by endogenous PLB (Waggoner et al., 2009). Therefore,
while NKA and SERCA share many characteristics (which partly led to the central
hypothesis of the studies described here) they also have important differences, and
the properties of one cannot reliably be predicted based on the observed properties
of the other.
As in rabbits, it is likely that NKA is not saturated by endogenous PLM in
humans either, since PLM is known to be basally phosphorylated in human hearts
(El-Armouche et al., 2011). This underscores the potential for overexpression of WT
PLM in humans to increase PLM-NKA binding, possibly leading to increased NKA
inhibition and increased contractility.
L30A PLM increased the amplitude of the Ca2+ transient and the decay
constant compared to WT overexpression. It also increased the duration of the
contraction. These results suggest that for L30A, increased PLM-NKA binding led to
increased inhibiton of NKA, although I was unable to test that directly. In contrast,
for gain-of-NKA-binding mutants L27A and I32A, no differences in comparison to
WT overexpression were observed. This indicates that increasing PLM-NKA binding
does not necessarily mean increased NKA inhibition. Still, the rationale of testing
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gain-of-binding mutants for functional effects is logical, and it resulted in the
discovery of L30A as a positively inotropic mutant.
After β-adrenergic stimulation, no detectable differences between L30A and
WT PLM were observed, suggesting that the effects of L30A may be reversible. This
is further supporting evidence for the idea that L30A PLM could be used in a
therapeutic approach for the treatment of HF, and that this therapy could be
superior to cardiac glycosides. In Figure 23, I have contrasted these
pharmacological and physiological approaches to inhibiting NKA and increasing
cardiac contractility. Glycosides inhibit a fraction of the NKA pumps, leading to
increased [Na+]i and inhibition of Ca2+ extrusion by NCX. This increases SR Ca2+ load
and cardiac contractility. However, [Na+]i is already elevated in HF (Despa et al.,
2002; Piacentino et al., 2003), and [Na+]i and SR Ca2+ overload can cause
arrhythmias. This can only be prevented by careful titration of the glycoside dose,
because inhibition of NKA by glycosides is not dynamically regulated in response to
adrenaline. In contrast, the effect of superinhibition of NKA by PLM may be
reversible; the Ca2+ transients and myocyte contractions of cells expressing WT
versus L30A PLM converged following β-adrenergic stimulation. Additionally, while
glycosides decrease the Vmax of NKA, increasing the risk of Na+-overload and
arrhythmogenesis, PLM decreases the activity of NKA (by decreasing Na+ affinity)
but preserves Vmax (Bossuyt et al., 2009; Despa et al., 2005; Han et al., 2009). This
could mean a broader therapeutic window for superinhibityory PLM, because a rise
in [Na+]i would be limited by reserve NKA activity. Thus, both PLM phosphorylation

and relief of NKA inhibition by high

[Na+]i
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could provide physiological reversibility

during stress.
If a PLM mutant like L30A were to be used in a clinical setting, the means of
delivery to the patient would be through gene therapy. This involves the
administration of a viral vector containing the DNA sequence for the protein to be
expressed. Like with the cardiomyocyte experiments performed here, the L30A
PLM gene could be inserted into an adenovirus genome, and then applied directly to
the cardiac tissue using catheterization. This approach is currently being tested in a
clinical trial for HF patients called CUPID. In HF, SERCA expression is known to be
downregulated, and the goal of the gene therapy in CUPID is to rescue SERCA
expression through exogenous delivery in an adenoviral vector (Jaski et al., 2009).
So far, the results are encouraging (Zsebo et al., 2014).
These results notwithstanding, there are still many obstacles to overcome
before gene therapy is approved for widespread use (Cotrim & Baum, 2008).
Questions remain as to how exogenous gene expression can be controlled longterm. Will the virus need to be reapplied? How can physicians turn off exogenous
gene expression if it becomes too high? Answering these questions is beyond the
scope of this current project. However, the evidence presented in this report
suggests that if gene therapy becomes a viable treatment option in the future,
exogenous delivery of WT or L30A PLM could help patients with HF.
The work presented here could be furthered by future experimentation.
There are several other candidate mutants from the FRET screen, such as I23A or
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L33A, that have yet to be tested for effects on cardiomyocytes. Other mutants could
be designed and tested as well, such as double or triple alanine substitutions that
could yield a mutant with even greater effects than L30A. Ideally, mutants would be
tested in an in vivo model of HF to see if exogenous expression actually relieves
symptoms for animals, if overexpression is arrhythmogenic, or if PLM-NKA binding
can be dynamically regulated to avoid arrhythmias. These later experiments would
be necessary before PLM gene therapy could be pursued with humans.
Furthermore, the experiments performed here employed the use of fluorescent
protein fusion constructs. The effect of these fluorescent tags on protein function
has not been directly tested, and therefore further testing with untagged PLM
mutants should be performed.
In summary, the goal of this project was to test the hypothesis that mutation
of TM domain PLM residues would lead to increased NKA inhibition and positive
inotropy that would be physiologically reversible. Based on my results, I propose a
new model where WT PLM overexpression results in increased binding to NKA and
increased contractility; L30A PLM increases NKA binding and contractility even
further, but there is no difference between WT- and L30A-expressing myocytes after
β-adrenergic stimulation.
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Figure 23. Pharmacological versus physiological inhibition of NKA. (A) Cardiac
glycosides act by binding to and inhibiting the activity of NKA in the sarcolemma of
cardiomyocytes (1). This leads to an increase in [Na+]i, which inhibits the ability of
NCX to extrude Ca2+ (2). As [Ca2+] rises in the cytosol and in the SR (3), contractility
is increased as intended. However, overdose of cardiac glycosides leads to overload
of Ca2+ in the SR and leakage out of the SR, potentially causing an arrhythmia (4).
(B) In this study, L30A PLM displayed increased binding to NKA (compared to WT
PLM), and mimicked the effects of cardiac glycosides on isolated cardiomyocytes.
Following β-adrenergic stimulation, which is known to cause PLM phosphorylation,
there were no differences between WT- and L30A-overexpressing cells, suggesting
that the effect of L30A mutation may be physiologically reversible.
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